Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Inclisiran (Leqvio) vs Nicotinamide Riboside: Nicotinamide Riboside has the stronger overall evidence (5.5 vs 4.1/10); they're alternatives for support heart health — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Nicotinamide Riboside wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Too few graded studies
Top outcomes
Verdict
Too few graded studies
Top outcomes
284 mg (300 mg inclisiran sodium) by subcutaneous injection administered by a healthcare professional on day 1, again at day 90 (month 3), then every 6 months thereafter. A prescription drug; this is the approved regimen, not a self-directed supplement protocol.
Any time of day
Prefilled subcutaneous injection (inclisiran 284 mg)
1000 mg daily (the dose used in most outcome trials; lower doses raise blood NAD+ but have not been tested for clinical effects)
Morning with breakfast, Split dosing (morning and midday) for doses above 500 mg
Nicotinamide Riboside Chloride capsules or powder
and 1 more not shown
Weeks to months; sustained
Ongoing
Outcomes trials ongoing
Around each injection
1–2 weeks
4–8 weeks
8–16 weeks
4–8 weeks
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
The New England journal of medicine (2020) · Rct · n=3178
ORION-10 and ORION-11 randomized, placebo-controlled phase 3 trials in atherosclerotic cardiovascular disease / high risk
Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia.
The New England journal of medicine (2020) · Rct · n=482
ORION-9 randomized, placebo-controlled phase 3 trial in heterozygous familial hypercholesterolemia
Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol.
The New England journal of medicine (2017) · Rct · n=501
ORION-1 phase 2, double-blind, placebo-controlled, multiple-ascending-dose trial
NAD⁺ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence.
Ageing Research Reviews (2026) · Systematic review
Reviewed 113 intervention studies published from 2010 to October 2025: 33 in humans (28 of them randomised) and 80 in rodents, covering NR, NMN and injected NAD+.
The Effect of Nicotinamide Mononucleotide and Riboside on Skeletal Muscle Mass and Function: A Systematic Review and Meta-Analysis.
Journal of Cachexia, Sarcopenia and Muscle (2025) · Meta analysis
Systematic review and meta-analysis of placebo-controlled RCTs of NMN or NR in adults with a mean age of 60.9 to 83 years, looking at muscle mass, grip strength, gait speed and other physical performance tests.
Effects of NAD+ precursor supplementation on glucose and lipid metabolism in humans: a meta-analysis.
Nutrition & Metabolism (2022) · Meta analysis · n=14750
Meta-analysis of 40 clinical studies (14,750 participants) of four NAD+ precursors: nicotinamide riboside, nicotinamide mononucleotide, nicotinic acid (niacin) and nicotinamide.
The points come from one 8-week RCT in overweight adults, where 100, 300 and 1,000 mg a day raised whole-blood NAD+ by 22%, 51% and 142%, with no difference in adverse events versus placebo or between doses (PMID 31278280). Other trials at 1 g a day found similar rises, 2.6-fold in older adults with mild cognitive impairment (PMID 37994989). No trial compared doses above 1,000 mg, so no optimal dose is plotted. The ceiling is the 2,000 mg a day that a 12-week RCT in obese men found safe (PMID 29992272). The NR-SAFE trial also found 3,000 mg a day well tolerated over 4 weeks in 10 people with Parkinson's disease (PMID 38016950).
AI-estimated from published studies. Interpret as directional guidance.
Nicotinamide Riboside has a higher evidence score (5.5/10 vs 4.1/10) and wins in 2 of 3 categories.
For support heart health, Inclisiran (Leqvio) has a higher relevance score (70 vs 62).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.